1. Home
  2. CRUS vs GRFS Comparison

CRUS vs GRFS Comparison

Compare CRUS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cirrus Logic Inc.

CRUS

Cirrus Logic Inc.

HOLD

Current Price

$144.29

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$9.29

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRUS
GRFS
Founded
1984
1940
Country
United States
Spain
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.2B
IPO Year
1989
2006

Fundamental Metrics

Financial Performance
Metric
CRUS
GRFS
Price
$144.29
$9.29
Analyst Decision
Strong Buy
Hold
Analyst Count
5
2
Target Price
$147.60
$10.15
AVG Volume (30 Days)
814.5K
449.6K
Earning Date
02-03-2026
07-28-2022
Dividend Yield
N/A
1.53%
EPS Growth
37.60
N/A
EPS
7.56
0.64
Revenue
$1,973,312,000.00
$8,821,017,248.00
Revenue This Year
$1.37
$5.36
Revenue Next Year
$2.76
$5.15
P/E Ratio
$18.79
$17.85
Revenue Growth
7.04
7.31
52 Week Low
$75.83
$6.19
52 Week High
$146.88
$11.14

Technical Indicators

Market Signals
Indicator
CRUS
GRFS
Relative Strength Index (RSI) 68.02 52.06
Support Level $139.26 $9.07
Resistance Level $146.88 $9.64
Average True Range (ATR) 6.77 0.21
MACD 0.73 -0.01
Stochastic Oscillator 82.83 42.47

Price Performance

Historical Comparison
CRUS
GRFS

About CRUS Cirrus Logic Inc.

Cirrus Logic Inc is a provider of integrated circuits for audio and voice signal processing applications. The firm's products are organized into two streams: portable audio products, and HPMS Products. These products include aAmplifiers, codecs, smart codecs, analog-to-digital converters, digital-to-analog converters and standalone digital signal processors, Camera controllers, haptics and sensing solutions, and battery and power ICs. Roughly half of the firm's revenue is generated in China, with the rest coming from the United States, Europe, South Korea, and countries across the world.

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Share on Social Networks: